Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Institutional Ownership : 42.45% (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Dicerna Pharmaceuticals's institutional ownership is 42.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Dicerna Pharmaceuticals's Insider Ownership is 0.41%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Dicerna Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 95.85%.

Dicerna Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Dicerna Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals Institutional Ownership Chart

Dicerna Pharmaceuticals Historical Data

The historical data trend for Dicerna Pharmaceuticals can be seen below:

	2021-02-28	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30
Institutional Ownership	65.43	66.33	60.72	60.73	59.55	56.37	54.28	52.15	45.57	42.45

Dicerna Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Hayden Avenue, Lexington, MA, USA, 02421

Website

https://www.dicerna.com

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.

Executives

Bob D Brown	officer: See Remarks	87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye	officer: EVP & Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin	director
Douglas Fambrough	director, officer: President and CEO	C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman	officer: Chief Operating Officer & EVP	C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia	officer: Chief Human Resources Officer	C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli	officer: Chief Commercial Officer	DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein	director	129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray	director	C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Martin I Freed	director	87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301